OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	264
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	208
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine	153
Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement	136
Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice	126
The dengue-specific immune response and antibody identification with machine learning	109
Assessing immunogenicity barriers of the HIV-1 envelope trimer	105
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	104
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	101
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	85
Rational development of a combined mRNA vaccine against COVID-19 and influenza	84
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	81
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	80
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	78
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	76
Mapping global public perspectives on mRNA vaccines and therapeutics	73
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	70
Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study	70
Reverse development of vaccines against antimicrobial-resistant pathogens	68
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	66
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	64
Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus	63
A viral codon usage strategy enhances antigen production and protection in SFTSV mRNA vaccination	63
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	60
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	60

Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	58
Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial	58
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	56
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	55
mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs	51
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	50
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	49
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	49
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	48
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	48
An open repository of COVID-19 vaccine mandate studies with a worked scoping review of quasi-experimental evidence	47
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters	46
Antibody responses against influenza A decline with successive years of annual influenza vaccination	44
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	44
PfRH5 vaccine; from the bench to the vial	43
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	43
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	43
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	42